Novo Nordisk Expands Insulin Manufacturing Facility in Denmark
Novo Nordisk broke ground on an expanded production plant for insulin in Kalundborg, Denmark.
Novo Nordisk is investing 400 million Danish kroner (more than 65 million USD) in a 500-m2 extension of what the company notes is the world's largest insulin production plant in Kalundborg, Denmark. Groundbreaking for the expansion took place on July 4, 2016 and is expected to be completed at the end of 2018.
"The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg. The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant," said Michael Hallgren, senior vice-president and head of production in Kalundborg, in a press release.
Established in 1969, the Kalundborg production site today covers a total area of 1.1 million m2. The facility produces 50% of the world's insulin as well as a range of biopharmaceutical products.
Source: Novo Nordisk
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
